<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369586</url>
  </required_header>
  <id_info>
    <org_study_id>MPZ-I-01</org_study_id>
    <nct_id>NCT04369586</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Trial of Meplazumab in Healthy Volunteer</brief_title>
  <official_title>A Single Center, Double-blinded, ,Placebo-controlled Phase I Clinical Trial in Healthy Volunteer to Evaluate Tolerance and Pharmacokinetics of Meplazumab of Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, double-blinded, placebo-controlled phase I clinical trail in healthy&#xD;
      volunteer of meplazumab for injection. The primary objective of this phase I trial is to&#xD;
      evaluate the safety, tolerability, pharmacokinetic characteristics and occupancy&#xD;
      characteristics of peripheral blood cell receptors of meplazumab in healthy volunteer, and&#xD;
      provide a reference for the dosage of meplazumab in phase II clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2020</start_date>
  <completion_date type="Actual">November 20, 2020</completion_date>
  <primary_completion_date type="Actual">August 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>0-28 days</time_frame>
    <description>Nature, incidence, and severity of AEs/SAEs, and the relationship to meplazumab treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments of meplazumab- AUC0-tn</measure>
    <time_frame>0-28 days</time_frame>
    <description>AUC0-tn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments of meplazumab- AUC0-∞</measure>
    <time_frame>0-28 days</time_frame>
    <description>AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments of meplazumab-half life time</measure>
    <time_frame>0-28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments of meplazumab-Cmax</measure>
    <time_frame>0-28 days</time_frame>
    <description>Maximum observed plasma concentration of meplazumab (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>meplazumab dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.06mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.12mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.42mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.56mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3mg/kg for double doses, 1 dose/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meplazumab for injection</intervention_name>
    <description>single dose: 6 dose level, multiple dose: 0.3mg/kg/dose</description>
    <arm_group_label>meplazumab dose 1</arm_group_label>
    <arm_group_label>meplazumab dose 2</arm_group_label>
    <arm_group_label>meplazumab dose 3</arm_group_label>
    <arm_group_label>meplazumab dose 4</arm_group_label>
    <arm_group_label>meplazumab dose 5</arm_group_label>
    <arm_group_label>meplazumab dose 6</arm_group_label>
    <arm_group_label>meplazumab multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>meplazumab dose 1</arm_group_label>
    <arm_group_label>meplazumab dose 2</arm_group_label>
    <arm_group_label>meplazumab dose 3</arm_group_label>
    <arm_group_label>meplazumab dose 4</arm_group_label>
    <arm_group_label>meplazumab dose 5</arm_group_label>
    <arm_group_label>meplazumab dose 6</arm_group_label>
    <arm_group_label>meplazumab multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18≤age≤50 years, males or females;&#xD;
&#xD;
          -  body weight ≥50 kg, body mass index (BMI) should be within 19.0 and 24.0 (both ends&#xD;
             included),&#xD;
&#xD;
          -  Vital signs, physical examination, laboratory examination (blood routine, urine&#xD;
             routine, blood biochemical, coagulation, etc.) and electrocardiogram are within the&#xD;
             normal range, or beyond the normal range, but the researchers determined that the&#xD;
             abnormality has no clinical significance (NCS).&#xD;
&#xD;
          -  No bad habits, including tobacco addiction (&gt;5 cigarettes per day) or drink addiction&#xD;
             (&gt;15 g of alcohol in a day, and more than two days a week for female, or &gt;25 g in a&#xD;
             day, and more than two days a week for male; 15 g of alcohol is equivalent to 450 mL&#xD;
             beer, 150 mL wine or 50 mL light liquor), no history of drug abuse (defined as the use&#xD;
             of illegal drugs);&#xD;
&#xD;
          -  No birth plan during the study and within 6 months of completing the test and are&#xD;
             willing to use non-hormonal contraceptive measures;&#xD;
&#xD;
          -  Have the ability to communicate normally with medical staff and comply with relevant&#xD;
             hospital management regulations;&#xD;
&#xD;
          -  Understand the study and be willing to participate in the study, and sign an informed&#xD;
             consent form. Incompetent subjects, willing and able to comply with all trial&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergies to drugs, food, protein or specific allergies (asthma, rubella,&#xD;
             eczema dermatitis, etc.);&#xD;
&#xD;
          -  Vital signs, physical examination, routine laboratory tests (blood routine, urine&#xD;
             routine, blood biochemistry, coagulation, etc.), 12-lead ECG and other abnormalities&#xD;
             and clinical significance;&#xD;
&#xD;
          -  Positive for SARS-CoV-2 specific IgM and IgG antibodies test;&#xD;
&#xD;
          -  Fever within 3 days before medication (body temperature ≥38.0 ℃);&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Have received or are participating in other clinical trials within 3 months before the&#xD;
             screening;&#xD;
&#xD;
          -  Be diagnosed or suspected to have immunodeficiency or autoimmune diseases; undergo&#xD;
             immunosuppressive therapy such as anticancer chemotherapy or radiotherapy before the&#xD;
             trial, or have received systemic corticosteroid treatment within the past 6 months;&#xD;
&#xD;
          -  With a history of acupuncture syncope reaction;&#xD;
&#xD;
          -  Positive for HBV surface antigen, anti-HCV antibody, anti-HIV antibody, and syphilis&#xD;
             antibody test;&#xD;
&#xD;
          -  Tobacco addiction (&gt;5 cigarettes per day) or drink addiction (&gt;15 g of alcohol in a&#xD;
             day, and more than two days a week for female, or &gt;25 g in a day, and more than two&#xD;
             days a week for male; 15 g of alcohol is equivalent to 450 mL beer, 150 mL wine or 50&#xD;
             mL light liquor), or can not stop smoking and drinking during the study;&#xD;
&#xD;
          -  Participated in blood donation or blood loss ≥400mL within 3 months before screening;&#xD;
&#xD;
          -  Patients not suitable to participate in this study by the judgment of the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hospital of the Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

